Don’t see coverage of an asset you’re looking for? Let us know and we’ll add it to future snacks.

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Stryker SYK has outperformed the market over the past 20 years by 2.57% on an annualized basis producing an average annual return of 10.84%. Currently, Stryker has a market capitalization of $145. ...

This month's cover highlights the article Malaria parasites undergo a rapid and extensive metamorphosis after invasion of the host erythrocyte by Christiaan van Ooij, Aline Fréville and colleagues.

CTL escape is an important mechanism by which the virus evades the immune response. The occurrence and timing of escape depends on a variety of factors. Similarly, the significance of escape for ...

Below is Validea's guru fundamental report for STRYKER CORP (SYK). Of the 22 guru strategies we follow, SYK rates highest using our Multi-Factor Investor model based on the published strategy of ...

Stryker SYK recently received FDA clearance for its OptaBlate BVN Basivertebral Nerve Ablation System (OptaBlate BVN), a significant milestone in the treatment of chronic vertebrogenic lower back ...

OBJECTIVE This study aimed to identify potential synthetic peptides from C-type lectin 1 (Tc-CTL-1) from Toxocara canis. BALB/c specific pathogen free (SPF) mice were used for experiments with S.

Medical technology company Stryker (NYSE:SYK) announced better-than-expected revenue in Q1 CY2025, with sales up 11.9% year on year to $5.87 billion. Its non-GAAP profit of $2.84 per share was 4% ...